Reneo Pharmaceuticals Analyst Ratings
Reneo Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 265.41% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 09/08/2023 | 265.41% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 08/28/2023 | 265.41% | HC Wainwright & Co. | → $30 | Initiates Coverage On | → Buy |
| 07/03/2023 | 180.15% | B of A Securities | → $23 | Initiates Coverage On | → Buy |
| 09/19/2022 | 277.59% | HC Wainwright & Co. | → $31 | Assumes | → Buy |
| 05/18/2022 | 119.24% | Piper Sandler | $45 → $18 | Maintains | Overweight |
| 03/24/2022 | 82.7% | SVB Leerink | $25 → $15 | Maintains | Outperform |
| 01/27/2022 | 241.05% | Baird | → $28 | Initiates Coverage On | → Outperform |
| 12/21/2021 | 241.05% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 11/22/2021 | 448.11% | Ladenburg Thalmann | → $45 | Initiates Coverage On | → Buy |
| 05/04/2021 | 204.51% | SVB Leerink | → $25 | Initiates Coverage On | → Outperform |
| 05/04/2021 | 192.33% | Jefferies | → $24 | Initiates Coverage On | → Buy |
| 05/04/2021 | 448.11% | Piper Sandler | → $45 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月12日 | 265.41% | HC Wainwright公司 | →$30 | 重申 | 購買→購買 |
| 09/08/2023 | 265.41% | HC Wainwright公司 | →$30 | 重申 | 購買→購買 |
| 2023年08月28日 | 265.41% | HC Wainwright公司 | →$30 | 開始承保 | →購買 |
| 07/03/2023 | 180.15% | B of A證券 | →$23 | 開始承保 | →購買 |
| 2022/09/19 | 277.59% | HC Wainwright公司 | →$31 | 假設 | →購買 |
| 2022/05/18 | 119.24% | 派珀·桑德勒 | $45→$18 | 維護 | 超重 |
| 03/24/2022 | 82.7% | SVB Leerink | $25→$15 | 維護 | 跑贏大盤 |
| 2022年01月27日 | 241.05% | 貝爾德 | →$28 | 開始承保 | →跑贏大盤 |
| 2021/12/21 | 241.05% | HC Wainwright公司 | →$28 | 開始承保 | →購買 |
| 2021年11月22日 | 448.11% | 拉登堡·塔爾曼 | →$45 | 開始承保 | →購買 |
| 05/04/2021 | 204.51% | SVB Leerink | →$25 | 開始承保 | →跑贏大盤 |
| 05/04/2021 | 192.33% | 傑富瑞 | →$24 | 開始承保 | →購買 |
| 05/04/2021 | 448.11% | 派珀·桑德勒 | →$45 | 開始承保 | →超重 |
What is the target price for Reneo Pharmaceuticals (RPHM)?
雷諾製藥(Reneo PharmPharmticals)的目標價是多少？
The latest price target for Reneo Pharmaceuticals (NASDAQ: RPHM) was reported by HC Wainwright & Co. on October 12, 2023. The analyst firm set a price target for $30.00 expecting RPHM to rise to within 12 months (a possible 265.41% upside). 4 analyst firms have reported ratings in the last year.
雷諾製藥(納斯達克代碼：RPHM)的最新目標價是由HC Wainwright&Co.於2023年10月12日報道的。這家分析公司將目標價定為30美元，預計RPHM將在12個月內上漲至(可能上漲265.41%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Reneo Pharmaceuticals (RPHM)?
Reneo PharmPharmticals(RPHM)的最新分析師評級是多少？
The latest analyst rating for Reneo Pharmaceuticals (NASDAQ: RPHM) was provided by HC Wainwright & Co., and Reneo Pharmaceuticals reiterated their buy rating.
分析師對雷諾製藥(納斯達克代碼：RPHM)的最新評級由HC Wainwright&Co.提供，雷諾製藥重申其買入評級。
When is the next analyst rating going to be posted or updated for Reneo Pharmaceuticals (RPHM)?
Reneo PharmPharmticals(RPHM)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reneo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reneo Pharmaceuticals was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Reneo PharmPharmticals的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Reneo製藥的上一次評級是在2023年10月12日提交的，所以你應該預計下一次評級將在2024年10月12日左右的某個時候公佈。
Is the Analyst Rating Reneo Pharmaceuticals (RPHM) correct?
分析師對Reneo PharmPharmticals(RPHM)的評級正確嗎？
While ratings are subjective and will change, the latest Reneo Pharmaceuticals (RPHM) rating was a reiterated with a price target of $0.00 to $30.00. The current price Reneo Pharmaceuticals (RPHM) is trading at is $8.21, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Reneo PharmPharmticals(RPHM)評級被重申，目標價在0.00美元至30.00美元之間。雷諾製藥(Reneo PharmPharmticals)目前的交易價格為8.21美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。